Once-weekly semaglutide significantly reduces hospital admissions and total hospital stay in patients with cardiovascular disease and obesity.

Five- and 10-year surgical recurrence rates are low after ileocolic resection in Crohn disease in the biologic era.

Adding elraglusib, a novel small-molecule inhibitor, to chemotherapy significantly increases overall survival (OS) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma ...

Below is a review of novel drug and biological products approved by the Food and Drug Administration (FDA) in 2025. The list includes several groundbreaking therapies that are expected to change the ...

The Whole Milk for Healthy Kids Act let schools in the National School Lunch Program offer whole and 2% milk plus skim and low-fat choices.

Point-of-care hepatitis C virus RNA testing significantly increased testing costs compared with previous testing protocols.

Eight weeks of treatment with cinitapride improves symptom remission among patients with functional dyspepsia.

Replacing habitual artificial sweetened beverage intake with water does not improve glycemic outcomes or HbA1c levels in patients with T2D.

Higher antibody response toward Lachnospiraceae flagellin was associated with risk for CD among first-degree relatives of patients with CD.

The FDA's policy regarding mifepristone aligned with recommendations made by the agency’s scientists from 2011 to 2023.

In this study from ASCO GI 2026, researchers presented a 4-year follow-up of the phase 3 CheckMate 9DW trial of nivolumab plus ipilimumab in treatment-naïve HCC.

Patients with colorectal cancer who walked as exercise after their diagnosis reported cancer-related fatigue and higher quality-of-life.